Generic medicines specialist Sandoz is to be listed on the SIX Swiss stock exchange as a fully independent entity on Wednesday after being spun-off by pharma giant Novartis.
This content was published on
2 minutes
Keystone-SDA
Novartis took the decision to spin off its subsidiary in August 2022, as part of its own transformation towards becoming a more focused pharmaceutical company.
Novartis shareholders get one Sandoz title for every five shares. The same breakdown applies to American Depositary Receipts (ADRs). A total of 431 million shares will be issued, and Sandoz will be listed from the start in the Swiss Leader Index (SLI), which includes the 30 biggest listings on the Zurich stock exchange.
Based on initial pre-market indications, Sandoz’s market capitalisation is likely to be a little under CHF20 billion ($21.7 billion). Novartis was worth CHF209 billion on Tuesday evening.
“Today marks the beginning of a new era for Sandoz as an independent company, but our goal remains unchanged: to be a pioneer in access to medicines for patients,” Sandoz chairman Gilbert Ghostine said in a press release.
Sandoz was founded in 1886, while the pharmaceutical company Novartis was created in 1996 via a merger with Ciba-Geigy. Initially just part of a division, Sandoz became an independent reporting unit in 2005.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Swiss Abroad
An eye-opening guide to Switzerland’s ear-splitting sirens
This content was published on
Thomas Schinecker, CEO of Swiss pharma firm Roche, has dismissed fears that sales targets would be under threat by US tariffs.
This content was published on
Researchers are asking the Swiss public for help in naming two newly discovered Swiss fish species of the genus Barbatula.
Science alliance warns against Swiss government’s cost-cutting plans
This content was published on
An alliance of research and science institutions have warned of dire consequences if the Swiss government goes ahead with its austerity package.
Accidents during leisure time on the rise in Switzerland
This content was published on
IN 2024 more people had accidents during leisure time than in the previous year. Some 26% of all sports accidents happened playing football.
This content was published on
Apple's iPhones have gained further market share in Switzerland. Around half of all smartphone owners used a model from the US tech giant last year.
Switzerland receives poor marks in fight against public sector corruption
This content was published on
Switzerland is not improving in the fight against corruption according to the Corruption Perceptions Index published by Transparency International.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.